Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

NCT01511198 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of metformin and liraglutide on body weight in adults with type 2 diabetes who were previously treated with oral diabetes medication.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 223 people

Who can join Ages 18–75 · all sexes

Timeline Started 2001-02 · est. completion 2001-10

Where 39 sites · United States

What this study is testing ClinicalTrials.gov NCT01511198 ↗

Description as written by the study sponsor.

This trial is conducted in the United States of America (USA). The aim of this trial is to determine the dose-response relationship for body weight and five escalating doses of NNC 90-1170 (liraglutide) in subjects with type 2 diabetes previously treated with an oral hypoglycemic agent (OHA).

Treatments tested

liraglutide also known as NNC 90-1170 Drug

Injected subcutaneously once daily
metformin Drug

1000 mg twice daily, administered orally

Main thing measured	Body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01511198 ↗